SavedAdd your journal

Journals / Türkderm Türk deri hastalıkları ve frengi arşivi / 2022 / Cilt: 56 - Sayı: 1

Ixekizumab

İksekizumab

İlgen ERTAM SAĞDUYU
Pages
55–57
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It has been approved by the FDA for use in moderate psoriasis in patients aged between 6 and 18 years.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Ixekizumab is a human immunoglobulin G4 monoclonal antibody targeting interleukin-17A.
📊
Key Findings & Data:Clinical trials have reported that 82-84% of the patients using ixekizumab achieved a PASI90 response at week 12 and 85% at week 60.
💡
Conclusion & Impact:It has been approved by the FDA for use in moderate psoriasis in patients aged between 6 and 18 years.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Ixekizumab is a human immunoglobulin G4 monoclonal antibody targeting interleukin-17A. Clinical trials have reported that 82-84% of the patients using ixekizumab achieved a PASI90 response at week 12 and 85% at week 60. It has been found effective in chronic plaque psoriasis as well as genital, hairy skin, nail, and generalized pustular psoriasis in adults. It has been approved by the FDA for use in moderate psoriasis in patients aged between 6 and 18 years.

Özet

İksekizumab interlökin-17A’ya yönelik immünoglobulin G4 tipinde insan kaynaklı bir monoklonal antikordur. Klinik araştırmalarda PAŞİ90 yanıtı elde edilen hasta oranı 12. haftada %82-84 arası, 60. haftada ise %85 olarak bildirilmiştir. Erişkinlerde kronik plak tip psoriasisin yanında genital, saçlı deri, tırnak ve generalize püstüler tip psoriasiste de etkili bulunmuştur. Altı-18 yaş arası hastalarda da orta şiddetli psoriasiste kullanımı için FDA onayı bulunmaktadır.

🔖

Cite This Article

SAĞDUYU, İ. E. (2022). Ixekizumab. Türkderm Türk deri hastalıkları ve frengi arşivi, Cilt: 56 - Sayı: 1, 55–57. https://ajindex.com/articles/622424

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Syed YY: Iksekizumab: a review in moderate to severe plaque psoriasis. Am J Clin Dermatol 2017;18:147-58
  2. Blegvad C, Skov L, Zachariae C: İksekizumab for the treatment of psoriasis: an update on new data since first approval. Expert Rev Clin Immunol 2019;15:111- 21
  3. Markham A: Ixekizumab: First global approval. Drugs 2016;76:901-5
  4. Gordon KB, Blauvelt A, Papp KA, et al.: Phase 3 trials of iksekizumab in moderateto-severe plaque psoriasis. N Engl J Med 2016;375:345-56
  5. Leonardi C, Reich K, Foley P, et al.: Efficacy and safety of iksekizumab Through 5 years in moderate-to-severe psoriasis: long-term results from the UNCOVER-1 and UNCOVER-2 phase-3 randomized controlled trials. Dermatol Ther (Heidelb) 2020;10:431-47
  6. Griffiths CE, Reich K, Lebwohl M, et al.: Comparison of iksekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015;386:541-51
  7. Lebwohl MG, Gordon KB, Gallo G, Zhang L, Paul C: İksekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study. J Eur Acad Dermatol Venereol 2020;34:301-9
  8. Fleming P: İksekizumab and psoriasis: an important entry into the therapeutic landscape. Br J Dermatol 2018;178:585-6
  9. Guenther L, Potts Bleakman A, Weisman J, et al.: İksekizumab Results in persistent clinical improvement in moderate-to-severe genital psoriasis during a 52 week, randomized, placebo-controlled, phase 3 clinical trial. Acta Derm Venereol 2020;100:adv00006
  10. Blauvelt A, Papp K, Gottlieb A, et al.: A head-to-head comparison of İksekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol 2020;182:1348-58
  11. Reich K, Pinter A, Lacour JP, et al.: Comparison of İksekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol 2017;177:1014-23
  12. Paller AS, Seyger MMB, Alejandro Magariños G, et al.: Efficacy and safety of İksekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol 2020;183:231-41
  13. Ryan C, Menter A, Guenther L, et al.: Efficacy and safety of İksekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with